Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

Faculty Opinions recommendation of Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725390739.793505250 ◽

2015 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Protease Inhibitor ◽

Inhibitor Therapy ◽

Protease Inhibitor Therapy ◽

Phase 2 ◽

Genotype 1 ◽

Double Blind ◽

Hcv Genotype ◽

Phase 2 Trial ◽

Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy

Clinical and Experimental Hepatology ◽

10.5114/ceh.2018.75957 ◽

2018 ◽

Vol 4 (2) ◽

pp. 83-90 ◽

Cited By ~ 3

Author(s):

Béla Hunyady ◽

Margit Abonyi ◽

Zsuzsanna Gerlei ◽

Judit Gervain ◽

Gábor Horváth ◽

...

Keyword(s):

Protease Inhibitor ◽

Inhibitor Therapy ◽

Protease Inhibitor Therapy ◽

Genotype 1 ◽

Hcv Genotype ◽

1059 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY OF NITAZOXANIDE WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN NONRESPONDERS (NR) WITH CHRONIC HCV GENOTYPE 1: WEEK 28 INTERIM ANALYSIS

10.1016/s0168-8278(09)61061-8 ◽

2009 ◽

Vol 50 ◽

pp. S385-S386 ◽

Cited By ~ 5

Author(s):

M. Shiffman ◽

A. Ahmed ◽

I. Jacobson ◽

R. Pruitt ◽

E. Keeffe

Keyword(s):

Interim Analysis ◽

Controlled Study ◽

Phase 2 ◽

Genotype 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

Chronic Hcv ◽

Peginterferon Alfa

1049 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY OF NITAZOXANIDE PLUS PEGINTERFERON AND RIBAVIRIN IN HCV GENOTYPE 1 PATIENTS: INTERIM ANALYSIS SHOWS INCREASE IN EVR

10.1016/s0168-8278(09)61051-5 ◽

2009 ◽

Vol 50 ◽

pp. S381 ◽

Cited By ~ 8

Author(s):

B. Bacon ◽

M. Shiffman ◽

J. Lim ◽

A. Berman ◽

V. Rustgi ◽

...

Keyword(s):

Interim Analysis ◽

Controlled Study ◽

Phase 2 ◽

Genotype 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Hcv Genotype ◽

Peginterferon And Ribavirin ◽

Faculty of 1000 evaluation for Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718020710.793480337 ◽

2013 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Genotype 1 ◽

Virus Genotype ◽

Double Blind ◽

Phase 2 Trial ◽

Pegylated Interferon Alfa

Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis

World Journal of Hepatology ◽

10.4254/wjh.v6.i10.759 ◽

2014 ◽

Vol 6 (10) ◽

pp. 759 ◽

Cited By ~ 3

Author(s):

Nicolae-Catalin Mechie

Keyword(s):

Protease Inhibitor ◽

Triple Therapy ◽

Meta Analysis ◽

Genotype 1 ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

Chronic Hcv

THU-192-All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive noncirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china

10.1016/s0618-8278(19)30467-0 ◽

2019 ◽

Vol 70 (1) ◽

pp. e247

Author(s):

Lai Wei ◽

xiaoyuan Xu ◽

yujuan Guan ◽

sujun Zheng ◽

Ji-Fang Sheng ◽

...

Keyword(s):

Clinical Trial ◽

Phase 2 ◽

Genotype 1 ◽

Hcv Genotype ◽

Treatment Naïve ◽

O114 RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION

10.1016/s0168-8278(14)60116-1 ◽

2014 ◽

Vol 60 (1) ◽

pp. S47 ◽

Cited By ~ 19

Author(s):

P. Kwo ◽

P. Mantry ◽

E. Coakley ◽

H. Te ◽

H. Vargas ◽

...

Keyword(s):

Liver Transplant ◽

Phase 2 ◽

Transplant Recipients ◽

Genotype 1 ◽

Hcv Genotype ◽

Phase 2 Study ◽

Hcv Genotype 1 ◽

Liver Transplant Recipients

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

Antiviral Research ◽

10.1016/j.antiviral.2013.05.015 ◽

2013 ◽

Vol 99 (3) ◽

pp. 214-220 ◽

Cited By ~ 25

Author(s):

Eric Lawitz ◽

Mark Sulkowski ◽

Ira Jacobson ◽

Walter K. Kraft ◽

Benedict Maliakkal ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Antiviral Activity ◽

Protease Inhibitor ◽

Genotype 1 ◽

Hcv Genotype ◽

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(13)70149-x ◽

2013 ◽

Vol 13 (7) ◽

pp. 597-605 ◽

Cited By ~ 147

Author(s):

Mark Sulkowski ◽

Stanislas Pol ◽

Josep Mallolas ◽

Hugo Fainboim ◽

Curtis Cooper ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Genotype 1 ◽

Virus Genotype ◽

Double Blind ◽

Phase 2 Trial ◽

Pegylated Interferon Alfa